Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:48:41 2024-03-28 am EDT 5-day change 1st Jan Change
964.7 USD -0.17% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.33% +9.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Regeneron Shares Down After FDA Letter Questioning Application for Potential Lymphoma Treatment MT
FDA Rejects Regeneron's Odronextamab in Follicular, Diffuse Large B-cell Lymphoma DJ
US FDA declines to approve Regeneron's blood cancer therapy RE
Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab CI
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron DJ
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
Regeneron Pharmaceuticals Insider Sold Shares Worth $5,531,290, According to a Recent SEC Filing MT
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy DJ
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-13-2024 10:40 AM
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM
Regeneron Says FDA Extends Approval of Praluent to Treat Children, Teens With Genetic High-Cholesterol MT
Regeneron Pharmaceuticals, Inc.'s Praluent® Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol CI
Regeneron Says Results From Phase 3 Trials of Eylea HD Met Their Primary Endpoints; Were Published by The Lancet MT
Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg CI
Boehringer to cut out-of-pocket costs for inhalers to $35 RE
Transcript : Regeneron Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-06-2024 11:10 AM
Regeneron Pharmaceuticals Insider Sold Shares Worth $346,365, According to a Recent SEC Filing MT
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $3,387,500, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $967,650, According to a Recent SEC Filing MT
Chart Regeneron Pharmaceuticals, Inc.
More charts
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
966.3 USD
Average target price
1,022 USD
Spread / Average Target
+5.78%
Consensus